

REMARKS

Claims 1 and 17-19 presently appear in this case. No claims have been allowed, although it is noted that none of the claims have been rejected over the prior art. The official action of April 20, 2007, has now been carefully studied. Reconsideration and allowance are hereby respectfully urged.

Briefly, the present invention relates to molecules comprising antibodies specific for RAP-2 or fragments of such antibodies that are capable of binding to RAP-2.

Claim 1 has been rejected under 35 U.S.C. 112, second paragraph, as being indefinite as it is not clear from the language of the claim whether the recitation of SEQ ID NO:4 refers to the antibody or the RAP-2 protein.

Claim 1 has now been amended to make it absolutely clear that SEQ ID NO:4 is the sequence of RAP-2.

Claim 17 has been rejected under 35 U.S.C. 112, second paragraph, as being indefinite in reciting the word "fraction." A claim from which it depends uses the term "fragment."

Claim 17 has now been amended to make this correction, thus obviating this rejection.

It is noted that the examiner has indicated that claims 1 and 17-19 are free of the prior art. Applicant is

Appln. No. 10/761,370
Amdt. dated April 30, 2007
Reply to Office action of April 20, 2007

disappointed that the examiner did not contact the undersigned by telephone in order to resolve by examiner's amendment the very minor and obvious corrections requested by the examiner, so as to expedite allowance of this case. In any event, it is believed that the present claims now obviate the only rejections of record and the application is now in condition for allowance. Accordingly, reconsideration and allowance are earnestly solicited.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant(s)

By /rlb/
Roger L. Browdy
Registration No. 25,618

RLB:jmd
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528
G:\BN\I\in12\Wallach27A\Pto\2007-04-30Amd.doc